Group items tagged

Market Overview: Skin substitutes are natural, synthetic or biosynthetic materials, used to cover large wounds to restore at least some of the functions of the skin. Skin substitutes provides temporary or permanent wound closure and protect the wound from infection, further damage and water loss, and reduce pain. They also facilitate the growth of the normal skin over the wound. Skin substitutes provide a permanent solution and are used in the treatment of conditions like burns, trauma wounds, diabetes or venous ulcers, where skin grafts may not be possible. Market Dynamics: Rising chronic skin diseases is expected to drive the skin substitutes market. For instance, according to the global burden of disease study 2013, Skin conditions contributed around 1.79% to the global disease burden. According to the World Health Organization, about 132,000 melanoma skin cancers occur each year worldwide. Thus, the rising chronic diseases is increasing the demand for skin substitutes in the forecast period. Rising prevalence of diabetes is expected to boost the market. This is owing to the risk of developing a diabetic foot ulcer over the period of time in diabetic patients. For instance, WHO has reported that the incidence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is anticipated to rise from 171 million in 2000 to 366 million in 2030. Thus, as a consequence, the prevalence of diabetes related complications are expected to increase over the forecast period. There are several limitations to the commercially available skin substitutes, like reduced vascularization, poor mechanical integrity, failure to integrate, scarring, and immune rejection. Market Segmentation: Rise in preference for acellular skin substitutes to implant-based skin surgery is expected to drive the growth of the skin substitutes market. For instance, the American Society of Plastic Surgeons in 2012, reported that

The Global Diabetic Foot Ulcer Market was valued at $4.48 billion in 2018 and is anticipated to exhibit 11.34% CAGR from 2019 to 2026, reaching $ XX billion by 2026.

Statins Can Cause Diabetes…Health regulators are including warning to the medicine labels of popular cholesterol-lowering drugs that they might increase blood sugar and possibly cause memory loss. FDA has publicized last week that there has been alterations in the safety information labels of statins of Merck & Co's, AstraZeneca and Pfizer - medicines that are used by millions of Americans. Statins have long proven that it is effective in reducing the risk of heart attack and other heart disorders and, according to FDA, this new development must not scare people into halting the use of the medicines. FDA announced that they know of studies wherein several patients taking statins might have an increased risk of having high sugar levels in the blood and, eventually, of being diagnosed with diabetes. DPRK jams GPS… "The special actions of our revolutionary armed forces will start soon to meet the reckless challenge of the group of traitors.... They will reduce all the rat-like groups and the bases for provocations to ashes in three or four minutes, in much shorter time, by unprecedented peculiar means and methods of our own style." From recent news |GPS jamming signals coming from North Korea has forced South Korea to order its military and civilian air transports to switch on alternative navigational devices to avoid disruption. A Los Angeles man was sentenced to six years in prison last week for his role in a power wheelchair scam, topping what prosecutors say has been a series of Medicare fraud cases.  Medicare Fraud…Whenever you get a payment notice from Medicare review it for errors. The notice shows what Medicare was billed for, what Medicare paid, and what (if anything) you owe. Make sure Medicare was not billed for health care services, medical supplies, or equipment you did not get. Linked to: http://www.ranker.com/list/springhill-group-korea/toffeex http://springhill-group.yolasite.com/ http://us.fotolog.com/springhillgroup/266000000000016012/

"An increase in brain inflammation, such as that caused by age, diabetes and obesity, is known to increase risk for developing Alzheimer's disease. Now scientists at UK's Southampton University are about to start a three-year study, using brain tissue generously donated by people who died with Alzheimer's disease, to see if inflammation caused by infections such as those of the urinary tract or chest, also speeds up progress of the disease." - medical news today In an announcement released on Wednesday, study leader Delphine Boche, Lecturer in Clinical Neurosciences at Southampton, says: "Many of the known risk factors for Alzheimer's, like age, obesity and diabetes, increase inflammation in the brain and we think that infections could be another risk factor." "There is already evidence that the immune system is on high alert in people with Alzheimer's and we think that an extra trigger, like an infection, could tip the balance and make immune cells switch from being protective to harmful," she adds. Alzheimer's Research UK has already put £300,000 into the project. The money is part of the charity's £20m investment in leading dementia research in the UK. The study started in January 2013, and will add to the growing pile of evidence that shows how the immune system is implicated in Alzheimer's disease. The Southampton team believes that in Alzheimer's, the immune system goes beyond its role as protector of the body and starts causing damage, like it does in an autoimmune disease. For their study, Boche and colleagues will use brain tissue generously donated by people who had Alzheimer's disease when they died. With reference to donors' medical records, the researchers will compare the brains of those who had infections when they died with those who did not. They will be particularly interested in immune cells known as "microglia", which go around mopping up cellular debris. They will use fluorescent tags to label the cells in the brain, and look

Health regulators are including warning to the medicine labels of popular cholesterol-lowering drugs that they might increase blood sugar and possibly cause memory loss. FDA has publicized last week that there has been alterations in the safety information labels of statins of Merck & Co's, AstraZeneca and Pfizer - medicines that are used by millions of Americans. Statins have long proven that it is effective in reducing the risk of heart attack and other heart disorders and, according to FDA, this new development must not scare people into halting the use of the medicines. FDA announced that they know of studies wherein several patients taking statins might have an increased risk of having high sugar levels in the blood and, eventually, of being diagnosed with diabetes. They have apparently known for 4 years now that statin 'slightly' increases blood sugar but they are insisting that this does not change that statins are effective in reducing heart risk for patients. This is the first time that FDA has officially connected the use of statin to cognitive disorders like confusion and forgetfulness, even though several patients have already reported those problems for years. The drugs affected include big brands such as Vytorin, Crestor, Zocor and Lipitor.

The global biopharmaceuticals market is set to exhibit a CAGR of 7.83% during 2019-2026 and is estimated to reach a market value of US $ XX billion by 2026. Biopharmaceuticals are large and complex molecular drugs that are mainly obtained from proteins and nucleic acids of living organisms such as microorganisms and animal cells also known as transgenic organisms. These drugs are obtained using biotechnology and have high-therapeutic value. Biopharmaceuticals are also known as biologics and biotech drugs and are usually administered by intravenous, subcutaneous, or intramuscular injections and are more efficient than the conventional small molecule drugs. Biopharmaceuticals are an alternative to the previously less effective and sometimes unsafe treatments and offer several benefits. Biopharmaceuticals benefits include highly effective and potent action, fewer side effects, can be tailored according to specific medical requirements of patients and they hold the potential to actually cure diseases at the root level. Biopharmaceuticals have reduced the number of deaths due to cancer and HIV/AIDS in the past decade and have changed the treatment of several chronic diseases, such as diabetes and cardiovascular diseases. Download free Report Sample: https://www.datamintelligence.com/download-sample/biopharmaceuticals-market View Full Report Sample: https://www.datamintelligence.com/research-report/biopharmaceuticals-market

Market Overview: Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026. Market Dynamics: The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. Market Segmentation: Based o